Search results

Following the trend in the world over and on the African continent, the Parliament of Ghana passed a new law in 2020, the Narcotics Control Commission Act (Act 1019) that eased the legal restrictions on cannabis cultivation and use, subject to obtaining license from the relevant authority/authorities. This paper aims to examine the implications of Ghana’s decision to legalise the cultivation of cannabis for industrial purposes for the production of fibre and for medicinal purposes.

The author adopted the qualitative analysis critical review methodology in sourcing information from peer-reviewed articles, coupled with the author’s own professional knowledge, background and training, to critically analyse and review the reasons behind Ghana’s decision to legalise cannabis cultivation and the implications such a major policy change/shift.

It was found that, while the law mentions industrial and medicinal purposes for the legalisation of cannabis, the real reason, at least in the immediate term, is mainly economic. This agrees with those of other African countries that have legalised cannabis cultivation but appears to contrast with those of Europe and America.

This research is limited to Ghana and the few African countries that have legalised cannabis cultivation so far. The main reason for the legalisation (economic benefits) may also change in the future when the economics of scale turn in the favour of the country. Therefore, Ghana’s case may not represent the case of all countries legalising cannabis cultivation.

The research implication of this paper is that it brings to the world the law on cannabis cultivation in Ghana. It provides a professional and scientific position paper on Ghana’s drug law regime regarding cannabis, thus, serving as a useful reference literature to the academic and research community on the topic. More importantly, it discusses the implications of such major policy change from an objective perspective, unravelling the real reason behind the State’s decision to legalise the cultivation of cannabis in Ghana.

This paper will bring to the fore the other consequences of Ghana’s cannabis cultivation legalisation policy change, which little attention has been devoted to so far.

This paper, apart from reference to other published texts on the topic, which have been duly acknowledged, represents the sole work of the author. It has not been produced anywhere or by anyone else either in Ghana or elsewhere.

Domestically produced, high potency cannabis (often referred to as ‘skunk’ in the mainstream UK media) has become increasingly widespread in the UK. This paper considers whether the trend reflects an increased awareness of and desire for medical marijuana. Determining whether cannabis is a drug or a medicine depends on its objective physiological effects ‐ which may vary from one individual to another ‐ as well as how and why those effects are experienced. The medicinal and mind‐altering effects of cannabis are not easily separable for many cannabis users. The medicinal use of cannabis in Britain has waxed and waned since the early 19th century. Currently, the UK is at the cutting edge of the development of cannabis‐based pharmaceuticals, but criminalises people who choose to self‐medicate with herbal cannabis. We are living in a time of political, social and economic uncertainty, which threatens the stability of national healthcare systems. The broad‐ranging effects of cannabis on the human body and mind, combined with its relatively easy cultivation, make it a sustainable and effective alternative medicine. Research is needed, especially on the experiences of people who use cannabis to benefit, enrich and even prolong their lives.

The purpose of this paper is to explore the characteristics of small-scale cannabis cultivation in New Zealand and Israel.

An online survey of predominantly small-scale cannabis cultivators had previously been conducted in 11 countries in 2012/2013. The same core online survey was subsequently conducted in New Zealand and Israel in 2016/2017, and comparisons made with the original 11 countries.

Only around one third of the New Zealand and Israeli cannabis growers had sold cannabis, and the majority of these did so only to cover the costs of cultivation. The median number of cannabis plants cultivated per crop by the New Zealand and Israeli growers was five and two, respectively. The leading reasons provided for growing cannabis by both the New Zealand and Israeli growers were to provide cannabis for personal use and to share with others. A higher proportion of New Zealand than Israeli growers reported growing cannabis for medicinal reasons. A total of 16 per cent of the New Zealand and 17 per cent of Israeli growers had come into contact with the police due to their cannabis cultivation. The findings suggest small-scale cannabis cultivation in New Zealand and Israel is largely a means of “social supply” of cannabis, and this is consistent with the findings from the original 11 countries. The higher incidence of growing cannabis for medicinal purposes in New Zealand may reflect the limited official access to medical cannabis. Significant minorities of small-scale cannabis growers in both countries had contact with police, putting them at risk of the negative consequences of a criminal conviction.

To date, the research into cannabis cultivation has largely consisted of studies of individual countries. However, given the global popularity of cannabis use, and the recent spread of cannabis cultivation to countries that traditionally have not produced cannabis, via utilisation of indoor growing techniques, there is now a strong case for international comparative research. Following the success of the surveys in the original 11 countries, New Zealand and Israeli members of the Global Cannabis Cultivation Research Consortium international collaboration chose to undertake surveys in their own countries in 2016/2017.

“Cannabis” and “cannabis resin” are derived from the Cannabis plant, used as herbal medications, in traditional medicine and as active pharmaceutical ingredients. Since 1961, they have been listed in Schedule IV, the most restrictive category of the single convention on narcotic drugs. The process to scientifically review and reschedule them was launched by the World Health Organisation (WHO) on 2 December 2016; it survived a number of hindrances until finally being submitted to a delayed and sui generis vote by the UN Commission on Narcotic Drugs on 2 December 2020, withdrawing “cannabis” and “cannabis resin” from Schedule IV.

To evaluate WHO’s scheduling recommendations, the process leading to the Commission vote and subsequent implications at global, national and patient/clinician levels. Narrative account of the four-year proceedings; review of the practical implications of both rejected and accepted recommendations.

The process was historically unprecedented, of political relevance to both medical Cannabis and evidence-based scheduling generally. Procedural barriers hampered the appropriate involvement of civil society stakeholders. The landscape resulting from accepted and rejected recommendations allow countries to continue creating decentralised, non-uniform systems for access to and availability of “cannabis” and “cannabis resin” for medical purposes.

Perspective of accredited observers; highlight of institutional issues and the lay of the land; contrast of stakeholders’ interpretations and engagement.

This study aims to explore people’s experiences of taking cannabis therapeutically and to gather some real-world evidence (RWE) about the products they were using, their efficacy and what kinds of positive or negative effect/s patients experienced. The focus of this discussion is the efficacy of cannabis for the participants in this study.

This was an exploratory study that used a mixed methods approach: a survey and semi-structured interviews. The data presented here focus on thematic analysis of five of the open-ended survey questions. Results from a purposive survey sample are also briefly reported. Interview data are not reported on here.

Across the sample (n = 213), 95.6% of participants reported that taking cannabis helped them with a number of conditions. The most common three themes across the thematic analysis were that cannabis helped with pain relief, sleep and anxiety. Negative effects, some of which related to having to source cannabis from the illicit market, were relatively minor and experienced by 28% (n = 58) of participants. An important finding was that 49% (n = 76) of those who said their use of prescribed medicines had decreased (n = 155), significantly decreased and in some cases stopped their use of prescribed medications.

This study reports on a sample of participants with clinically diagnosed conditions and adds to the RWE base about the efficacy of using cannabis for therapeutic purposes in the New Zealand context.

Despite 2016 legalization of recreational cannabis cultivation and sale in California with the passage of Proposition 64, many cannabis businesses operate without licenses. Furthermore, federal regulations disincentivize financial institutions from banking and lending to licensed cannabis businesses. The authors explore the impact of legal cannabis business activity on California financial institutions, the barriers to banking faced by cannabis businesses, and the nontraditional sources of financing used by the industry.

The authors use a mixed methods approach. The authors utilize call data for banks and credit unions headquartered in California and state cannabis licensing data to estimate the impact of the extensive and intensive margins of licensed cannabis activity on key banking indicators using difference-and-difference and fixed effects regressions. The qualitative data come from interviews with industry stakeholders in northern California's “Emerald Triangle” and add important context.

The quantitative results show economically and statistically significant impacts of licensed cannabis activity on banking indicators, suggesting both direct and spillover effects from cannabis activity to the financial sector. However, cannabis businesses report substantial barriers to accessing basic financial services and credit, leading to nontraditional financing arrangements.

The results suggest opportunities for cannabis businesses and financial institutions if regulations are eased and important avenues for further study.

The authors contribute to the nascent literature on cannabis economics and the literature on banking regulation and nontraditional finance.

The purpose of this paper to examine laws and regulations applicable to cannabis in the USA and the UK, including legal reforms and international treaty obligations.

This study relies on primary data from statutes and secondary data from online and offline resources, including relevant case studies.

Federal laws in the USA and existing UK cannabis legal regime generally prohibit recreational use of cannabis. Increasingly, various individual states in the USA have enabled the use of cannabis health-related uses, thereby challenging the status of the UN treaties on drug enforcement. As the USA struggles to reconcile the conflicts between federal law on cannabis and individual states within its borders, much of the rest of the world, including the UK, are struggling with how best to reconcile their domestic positions with their UN treaty obligations.

Recent disclosures of past recreational use of prohibited drugs by several candidates vying to be the UK Prime Minister suggests why understanding the laws governing the use of cannabis is useful and relevant to the general public.

This paper provides a general but integrated review of national laws in the USA and the UK, as well as international treaties governing the use of cannabis.

The purpose of this paper is to offer original ideas into a potential future cannabis industry in the UK. This paper presents novel approaches regarding the potential existence of cannabis for the tourism industry. It presents an idea in which the UK Government could produce, distribute and control the industry. The proposed idea presents a scheme in which the UK could encourage regional tourism (inclusive to domestic and international travellers) through a controlled but innovative cannabis market scheme. This paper presents a future scenario aiming to encourage dialogue and critique, at a time when attitudes to cannabis are changing.

This research takes a scenario narrative approach in presenting and exploring a potential future cannabis market in the UK. The importance of narrative writing as a method is recognised by Lindgren and Bandhold (2009), who identify the significance in telling a story to the reader. Taking a pragmatic approach, embracing diverse philosophical methods, this research explores past and current trends via a mixture of secondary data sources to create and present a scenario narrative of the future.

This paper identified that trends in legalising cannabis for cultivation, medical and recreational purposes continue to become more liberal globally. However, cannabis laws mainly focus on the use for residents. Consequently, domestic tourism markets have the potential to grow. However, there is limited consideration regarding the potential for international tourism cannabis markets. Thus, the findings of this research are based on the potential for the UK to implement and promote a cannabis industry for international travellers.

This paper offers original ideas in exploring a future cannabis market in the UK, one where regional tourism is considered. The paper presents a novel approach that encourages domestic and international tourists to engage with the cannabis industry by navigating a well-managed, local approach to supplying cannabis in the UK.